Preclinical development of tumor-infiltrating lymphocyte (TIL) based adoptive cell transfer (ACT) immunotherapy for patients with sarcoma

被引：0
|
作者：
Nielsen, M. [1 ]
Krarup-Hansen, A. [2 ]
Hovgaard, D. [3 ]
Petersen, M. M. [3 ]
Loya, A. C. [4 ]
Junker, N. [1 ]
Svane, I. M. [1 ]
机构：
[1] Herlev Hosp, Dept Oncol, Ctr Canc Immune Therapy, Copenhagen, Denmark
[2] Herlev Hosp, Dept Oncol, Copenhagen, Denmark
[3] Copenhagen Univ Hosp, Rigshosp, Dept Orthopaed Surg, Copenhagen, Denmark
[4] Copenhagen Univ Hosp, Rigshosp, Dept Pathol, Copenhagen, Denmark
来源：
ANNALS OF ONCOLOGY | 2016年 / 27卷
关键词：
D O I：
10.1093/annonc/mdw378.48
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1094P
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Preclinical development of tumor-infiltrating lymphocyte (TIL) based adoptive cell transfer (ACT) immunotherapy for patients with sarcoma and the potential benefit of anti-CD137 stimulation.
    Nielsen, Morten
    Krarup-Hansen, Anders
    Hovgaard, Dorrit
    Petersen, Michael Mork
    Loya, Anand Chainsukh
    Westergaard, Marie Christine Wulff
    Svane, Inge Marie
    Junker, Niels
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [2] Preclinical development of tumor-infiltrating lymphocytes (TILs) based adoptive cell transfer immunotherapy (ACT) for patients with advanced ovarian cancer
    Westergaard, M. C. W.
    Andersen, R.
    Kjeldsen, J. W.
    Hasselager, T.
    Lajer, H.
    Donia, M.
    Svane, I. -M.
    ANNALS OF ONCOLOGY, 2016, 27
  • [3] Pilot Trial of Ipilimumab and Adoptive Tumor-infiltrating Lymphocyte (TIL) Cell Therapy
    Prabhakaran, S.
    Woods, D. M.
    Royster, E. B.
    Zager, J. S.
    Sondak, V. K.
    Pilon-Thomas, S.
    Sarnaik, A. A.
    ANNALS OF SURGICAL ONCOLOGY, 2015, 22 : S23 - S23
  • [4] Expansion of tumor specific tumor-infiltrating lymphocytes (TIL) from sarcoma and the potential benefit of anti-CD137 stimulation: A prerequisite for adoptive cell transfer (ACT) immunotherapy
    Nielsen, M.
    Krarup-Hansen, A.
    Hovgaard, D.
    Petersen, M. M.
    Loya, A. C.
    Westergaard, M. C. W.
    Svane, I. M.
    Junker, N.
    ANNALS OF ONCOLOGY, 2017, 28
  • [5] Preclinical development of adoptive cell therapy with tumor-infiltrating lymphocytes for patients with renal cell carcinoma
    Andersen, R.
    Westergaard, M. C. W.
    Kjeldsen, J. W.
    Donia, M.
    Svane, I. M.
    ANNALS OF ONCOLOGY, 2015, 26 : 11 - 11
  • [6] Adoptive cell therapy (ACT) using tumor-infiltrating lymphocytes (TIL) for the treatment of bladder cancer.
    Bunch, Brittany L.
    Morse, Jennifer
    Asby, Sarah
    Poch, Michael
    Pilon-Thomas, Shari
    CLINICAL CANCER RESEARCH, 2020, 26 (15) : 31 - 31
  • [7] A Preclinical Model To Study Tumor. Infiltrating Lymphocyte (TIL) Anergy/Exhaustion in Adoptive T Cell Therapy (ACT) of Thoracic Malignancies
    Moon, Edmund K.
    Liang, Wang C.
    Caleph, Wilson
    Carpenito, Carmine
    Douglas, Dolfi
    James, Riley R.
    Wherry, John E.
    Carl, June H.
    Albelda, Steven M.
    MOLECULAR THERAPY, 2012, 20 : S95 - S95
  • [8] ADOPTIVE IMMUNOTHERAPY OF HUMAN CANCERS WITH TUMOR-INFILTRATING LYMPHOCYTES (TIL) AND INTERLEUKIN-2
    KRADIN, R
    DUBINETT, S
    SOLOVERA, J
    PREFFER, F
    IP, S
    KURNICK, J
    FASEB JOURNAL, 1988, 2 (04): : A445 - A445
  • [9] ACT Up TIL Now: The Evolution of Tumor-Infiltrating Lymphocytes in Adoptive Cell Therapy for the Treatment of Solid Tumors
    Hulen, Thomas Morgan
    Chamberlain, Christopher Aled
    Svane, Inge Marie
    Met, Ozcan
    IMMUNO, 2021, 1 (03): : 194 - 211
  • [10] Generation of tumor-infiltrating lymphocyte cultures for use in adoptive transfer therapy for melanoma patients
    Dudley, ME
    Wunderlich, JR
    Shelton, TE
    Even, J
    Rosenberg, SA
    JOURNAL OF IMMUNOTHERAPY, 2003, 26 (04): : 332 - 342
12345